One of the main objectives when assessing patients who react to antineoplastics must be to
ensure that they receive the required treatments without delay. From January to July 2021, at …

Background All platin-based chemotherapeutics can cause hypersensitivity reactions
(HSRs). With rapid drug desensitization (RDD), few patients experience breakthrough …

Although platin desensitization is a safe and effective alternative for patients with
hypersensitivity reactions (HSRs), sometimes breakthrough reactions (BTRs) can be …

Platin-based chemotherapeutic agents are associated with hypersensitivity reactions
(HSRs), occurring in 12% of patients with gynecologic malignancy receiving carboplatin. 1 …

Background Hypersensitivity reactions to antineoplastic agents may lead to discontinuation
of first-line treatments. Rapid drug desensitization (RDD) allows for a safe reintroduction in …

Platinum-based chemotherapy is the standard of care in a wide array of cancers. All
chemotherapy, including platinum derivates, can cause hypersensitivity reactions which …

Platinum‐containing chemotherapy agents (cisplatin, carboplatin, oxaliplatin) have been
approved in the first‐line setting of numerous malignancies, such as ovarian, bladder, head …

Background Drug desensitization is helpful for patients who have experienced significant
hypersensitivity reactions (HSRs) to antineoplastic agents. One-bag desensitization …

Purpose Repeated exposure to platinum compounds increases the risk of immunoglobulin E-
mediated immediate hypersensitivity reactions (HSR). To date, many different …

Platins are effective chemotherapy drugs used to treat ovarian and colon cancers among
others, but up to 25% of patients can develop life-threatening IgE-mediated hypersensitivity …